New Science Ventures

Pakal Technologies specializes in the development of IGTO-based semiconductors aimed at transforming the IGBT market. The company's semiconductors utilize IGTO, a silicon device designed as a direct replacement for IGBTs, offering substantial performance enhancements. This technology provides clients with efficient, scalable, and compatible semiconductor solutions to address power conversion challenges.

Glydways, based in South San Francisco, California, is a transportation technology and clean energy company focused on transforming mobility and public transportation. The company designs, manufactures, installs, and operates affordable autonomous transportation solutions that cater to low, medium, and high-capacity needs. Glydways' systems are engineered to operate profitably at existing mass transit fares while maintaining a small physical and environmental footprint. With zero greenhouse gas emissions, the company's transportation options provide a personal, private car experience, enhancing capacity at a reduced cost and carbon footprint.

Glydways, based in South San Francisco, California, is a transportation technology and clean energy company focused on transforming mobility and public transportation. The company designs, manufactures, installs, and operates affordable autonomous transportation solutions that cater to low, medium, and high-capacity needs. Glydways' systems are engineered to operate profitably at existing mass transit fares while maintaining a small physical and environmental footprint. With zero greenhouse gas emissions, the company's transportation options provide a personal, private car experience, enhancing capacity at a reduced cost and carbon footprint.

VUV Analytics, Inc. is a manufacturer and marketer of vacuum ultraviolet (VUV) detectors, specializing in advanced chemical analysis technologies. Founded in 2009 and based in Cedar Park, Texas, the company emerged as a spin-off from a semiconductor equipment firm, leveraging the expertise of its founders in hardware, software, and intellectual property related to VUV technologies. VUV Analytics produces instruments such as the VGA-100, a VUV absorption spectroscopy device, and gas chromatography detectors that facilitate the identification and quantification of various compounds. The company serves a diverse range of industries, including petroleum and natural gas, environmental science, specialty gases, petrochemicals, agrochemicals, forensics, and food and beverage safety. By harnessing light to create spectral signatures in the gas phase, VUV Analytics enhances the accuracy of chemical analysis, enabling customers to achieve unambiguous compound identification and quantitative results across complex applications.

Our view is a world where nothing is missed and one pair does it all. Because there’s more to see than ever before, and you deserve to see the bigger picture without edges or limitations. Our story starts with Jelle De Smet and Paul Marchal, two pioneers who with combined experience in electronics and nanotechnology invented the Autofocal lens. They saw a better way, where ageing eyesight is no longer a burden and progressive lenses were a prequel. And so Morrow was founded in 2016 — followed by years of research, development and meticulous fine-tuning. We now launch our flagship Autofocal Eyewear that combines Active Liquid Crystal and a two-layer corrective lens to transform your vision — both near and far — at the touch of a button. In our eyes, independence is a state of mind. It’s the unshackled freedom to do what you want and on your own terms, whilst always improving. Discover why there is always mor’ to see.

Paragraf Ltd. is a UK-based company established in 2015, specializing in the development and production of graphene-based electronic devices and materials. The company employs contamination-free technology to create high-purity graphene products, which are designed to enhance the performance of various electronic applications. Paragraf's innovations include devices for green energy generation, such as solar photovoltaic cells, as well as advanced sensors for monitoring environmental and health-related parameters. These products aim to optimize process and quality control across industries including electronics, energy, healthcare, and agriculture. By leveraging graphene's unique properties, Paragraf seeks to significantly impact the electronics industry and contribute to advancements in automation and disease research.

NorthSea Therapeutics B.V. is a biotechnology company based in Naarden, the Netherlands, focused on developing and manufacturing innovative therapeutics for metabolic, inflammatory, and fibrotic diseases. Founded in 2017, the company utilizes its proprietary Structurally Engineered Fatty Acid (SEFA) technology to create unique oral therapeutics, including icosabutate, which targets inflammatory and liver diseases. NorthSea Therapeutics aims to address various health conditions, such as dyslipidemia, insulin resistance, hepatic inflammation, and fibrosis, by delivering therapies that offer diverse biological effects. The company's pipeline reflects its commitment to advancing treatment options that enhance patient care and outcomes.

Cambridge Epigenetix Limited is a bioscience company based in Babraham, United Kingdom, specializing in epigenetic tools that aim to transform medical diagnostics. Founded in 2012 as a spin-out from the University of Cambridge, the company is pioneering the clinical applications of epigenetics, particularly through its innovative TrueMethyl technology. This includes oxidative bisulfite sequencing, which allows for the precise sequencing of hydroxymethyl cytosine and methylcytosine at single-base resolution. Cambridge Epigenetix offers a range of products, such as TrueMethyl 6 and TrueMethyl 24 kits, designed for the quantitative measurement and analysis of these critical epigenetic markers. The company’s research highlights the significance of 5-hydroxymethylcytosine as a biomarker for various diseases, including colorectal cancer, and aims to simplify diagnostic processes to a simple blood draw. The firm collaborates with third-party vendors and sells its products directly to business customers both in the UK and internationally.

BrightVolt, Inc. is a company focused on the design, development, and large-scale manufacturing of ultra-thin film batteries tailored to power a range of Internet-connected devices, including medical patches, sensor labels, and power cards. It specializes in creating custom solid-state thin film batteries and power solutions for clients' Internet of Things (IoT) devices, along with its proprietary Flexion solid-state thin film lithium polymer batteries and microelectronic components. BrightVolt's innovative technologies enhance battery chemistry, offering increased stability and safety in lithium-polymer batteries. The company's products are distributed both in the United States and internationally. Founded in 1998 and headquartered in Redmond, Washington, BrightVolt was previously known as Solicore, Inc.

Analog Inference is a company focused on advancing neural computing through innovative technology. Founded by experienced professionals from the computing industry and supported by Khosla Ventures, the company is developing its first generation of products. It specializes in deep sub-threshold analog in-memory computation, which allows for the execution of complex neural networks at full resolution while maintaining low latency and eliminating the need for active cooling. This technology enables the performance of data-center-grade artificial intelligence workloads with significantly reduced power consumption, facilitating the deployment of server-class networks in more cost-effective devices.

Phase Four LLC, founded in 2015 and based in Pasadena, California, specializes in the manufacture of satellite propulsion systems, particularly for small satellites. The company is known for its innovative Radio Frequency Thruster (RFT), which distinguishes itself by omitting traditional components such as hollow cathodes and high voltage electronics. This design leads to substantial benefits, including a tenfold reduction in materials costs compared to legacy electric propulsion systems, a significant decrease in the size of power electronics, and versatility in propellant use. Phase Four's propulsion solutions are utilized in various space missions, including commercial, civil, and scientific endeavors, and are engineered to optimize performance while maintaining a competitive thrust-to-power ratio. The company also offers products like the CubeSats ambipolar thruster and the Maxwell plasma propulsion solution, contributing to the efficient maneuvering of satellites across diverse orbital trajectories.

Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company based in Encinitas, California, that specializes in developing innovative therapies for autoimmune diseases and inflammatory disorders. Incorporated in 2018, Ventyx focuses on creating selective inhibitors targeting TYK2, a key mediator in various inflammatory conditions. The company's clinical pipeline includes VTX958, an oral allosteric TYK2 inhibitor currently in Phase 1 trials, which aims to provide a safer alternative by avoiding the toxicities linked to broader Janus kinase inhibition. Additionally, Ventyx is advancing VTX002, a Phase 2-ready S1P1 receptor modulator intended for ulcerative colitis treatment, and VTX2735, a Phase 1 peripheral inhibitor of the NLRP3 inflammasome, which plays a significant role in multiple inflammatory diseases.

Zeotap GmbH is a customer intelligence platform founded in 2014 and headquartered in Berlin, Germany, with additional offices in New York, Bengaluru, Madrid, and Milan. The company helps brands understand their customers and predict behaviors through its suite of data solutions, which includes the Zeotap Customer Data Platform (CDP), Zeotap Data, and Zeotap ID+. The Zeotap CDP allows brands to integrate, unify, segment, and orchestrate customer data securely and effectively. Zeotap Data enables targeted marketing at scale with access to a wide range of Champion Segments across various platforms. The Zeotap ID+ initiative provides a universal marketing ID to facilitate addressability in a future without cookies. Committed to privacy, Zeotap's platform adheres to stringent data security and privacy standards, empowering brands to leverage first-party data for enhanced customer engagement and loyalty.

ABL Space Systems is a company that designs and manufactures rockets specifically for launching small satellites. Founded in 2017 and headquartered in El Segundo, California, ABL focuses on developing low-cost and reliable launch vehicles. Its primary product, the RS1 rocket, is capable of carrying payloads of up to 1,350 kilograms to Low Earth Orbit (LEO) and supports various configurations, including multi-manifest and dedicated deployments. Additionally, ABL has developed the GS0 ground system to facilitate rapid deployment and integration of launch operations at multiple locations. The company operates out of a 30,000 square foot facility dedicated to research, development, and production.

NorthSea Therapeutics B.V. is a biotechnology company based in Naarden, the Netherlands, focused on developing and manufacturing innovative therapeutics for metabolic, inflammatory, and fibrotic diseases. Founded in 2017, the company utilizes its proprietary Structurally Engineered Fatty Acid (SEFA) technology to create unique oral therapeutics, including icosabutate, which targets inflammatory and liver diseases. NorthSea Therapeutics aims to address various health conditions, such as dyslipidemia, insulin resistance, hepatic inflammation, and fibrosis, by delivering therapies that offer diverse biological effects. The company's pipeline reflects its commitment to advancing treatment options that enhance patient care and outcomes.

DUST Identity, Inc. specializes in developing advanced authentication technology that employs nano-diamonds to create an unclonable identity layer on various objects within supply chains. Founded in 2011 and headquartered in Framingham, Massachusetts, with an additional office in Princeton, New Jersey, the company offers a proprietary system known as DUST, which includes an optical scanner and a cloud-based infrastructure. This system provides an interface for managing object identity and provenance, ensuring that products can be verified and trusted throughout their lifecycle. By linking physical items to their digital records, DUST Identity enables businesses to access critical data regarding product sourcing, testing, and certification, thereby enhancing safety and traceability across their value chains.

PlanetiQ LLC, founded in 2012 and based in Bethesda, Maryland, specializes in launching satellites designed to enhance weather forecasting, climate monitoring, and space weather prediction. The company leverages commercial satellite constellations to deliver critical weather data, addressing the increasing demand for precise forecasts amidst rising natural disaster costs and expanding populations. Traditional government-funded satellite programs have struggled to adapt to modern technological needs, resulting in aging spacecraft and budget constraints that jeopardize essential data collection. PlanetiQ aims to fill these gaps by providing timely and accurate data, which is vital for monitoring day-to-day weather events such as hurricanes, floods, and droughts, as well as long-term climate trends. Their services are intended to improve safety, reduce weather-related risks, and support decision-making across various sectors.

Paradigm Diagnostics specializes in advanced diagnostics technology for personalized cancer treatment. Using Next-Gen Sequencing and other biomarker analysis methods, the company provides detailed information about a patient's genomic and proteomic landscape, identifying specific characteristics of their tumor. This data is used to tailor treatment plans by matching potential therapies to the unique profile of each patient's cancer, thereby enhancing the effectiveness of clinical trials and improving outcomes for cancer patients.

BrightVolt, Inc. is a company focused on the design, development, and large-scale manufacturing of ultra-thin film batteries tailored to power a range of Internet-connected devices, including medical patches, sensor labels, and power cards. It specializes in creating custom solid-state thin film batteries and power solutions for clients' Internet of Things (IoT) devices, along with its proprietary Flexion solid-state thin film lithium polymer batteries and microelectronic components. BrightVolt's innovative technologies enhance battery chemistry, offering increased stability and safety in lithium-polymer batteries. The company's products are distributed both in the United States and internationally. Founded in 1998 and headquartered in Redmond, Washington, BrightVolt was previously known as Solicore, Inc.

DUST Identity, Inc. specializes in developing advanced authentication technology that employs nano-diamonds to create an unclonable identity layer on various objects within supply chains. Founded in 2011 and headquartered in Framingham, Massachusetts, with an additional office in Princeton, New Jersey, the company offers a proprietary system known as DUST, which includes an optical scanner and a cloud-based infrastructure. This system provides an interface for managing object identity and provenance, ensuring that products can be verified and trusted throughout their lifecycle. By linking physical items to their digital records, DUST Identity enables businesses to access critical data regarding product sourcing, testing, and certification, thereby enhancing safety and traceability across their value chains.

Svelte Medical Systems, founded in 2007 by Robert Fischell, David Fischell, and Tim Fischell, specializes in the design, development, and commercialization of balloon-expandable stents for treating atherosclerosis via percutaneous coronary intervention (PCI). The company offers two primary products: SLENDER Integrated Delivery System (IDS), a drug-eluting stent-on-a-wire system that facilitates transradial interventions by downsizing catheters; and DIRECT Rapid Exchange System (RX), a drug-eluting stent designed to enhance direct stenting and high-pressure post-dilatations. Svelte aims to improve stent deliverability, reduce costs, and enhance safety compared to existing market products in the $5 billion coronary stent market.

Isorg SA, founded in 2010 and based in Grenoble, France, specializes in the development and manufacturing of organic and printed electronic devices, particularly in the fields of photonics and image sensors. The company is noted for its innovative high-performance opto-electronic sensors, which can be integrated into various products, transforming surfaces made of plastic or glass into smart interfaces. Isorg offers a comprehensive range of services, from proof-of-concept to mass production, catering to diverse applications across consumer electronics, home appliances, smart buildings, industrial sectors, healthcare, and safety. Additionally, the company provides support for product development and integration. Its technology includes large-area image sensors and photodetectors, contributing to sectors such as medical imaging, non-destructive testing, and data security.

Cambridge Epigenetix Limited is a bioscience company based in Babraham, United Kingdom, specializing in epigenetic tools that aim to transform medical diagnostics. Founded in 2012 as a spin-out from the University of Cambridge, the company is pioneering the clinical applications of epigenetics, particularly through its innovative TrueMethyl technology. This includes oxidative bisulfite sequencing, which allows for the precise sequencing of hydroxymethyl cytosine and methylcytosine at single-base resolution. Cambridge Epigenetix offers a range of products, such as TrueMethyl 6 and TrueMethyl 24 kits, designed for the quantitative measurement and analysis of these critical epigenetic markers. The company’s research highlights the significance of 5-hydroxymethylcytosine as a biomarker for various diseases, including colorectal cancer, and aims to simplify diagnostic processes to a simple blood draw. The firm collaborates with third-party vendors and sells its products directly to business customers both in the UK and internationally.

Paradigm Diagnostics specializes in advanced diagnostics technology for personalized cancer treatment. Using Next-Gen Sequencing and other biomarker analysis methods, the company provides detailed information about a patient's genomic and proteomic landscape, identifying specific characteristics of their tumor. This data is used to tailor treatment plans by matching potential therapies to the unique profile of each patient's cancer, thereby enhancing the effectiveness of clinical trials and improving outcomes for cancer patients.

Our view is a world where nothing is missed and one pair does it all. Because there’s more to see than ever before, and you deserve to see the bigger picture without edges or limitations. Our story starts with Jelle De Smet and Paul Marchal, two pioneers who with combined experience in electronics and nanotechnology invented the Autofocal lens. They saw a better way, where ageing eyesight is no longer a burden and progressive lenses were a prequel. And so Morrow was founded in 2016 — followed by years of research, development and meticulous fine-tuning. We now launch our flagship Autofocal Eyewear that combines Active Liquid Crystal and a two-layer corrective lens to transform your vision — both near and far — at the touch of a button. In our eyes, independence is a state of mind. It’s the unshackled freedom to do what you want and on your own terms, whilst always improving. Discover why there is always mor’ to see.

ChromaCure is a biotechnology company focused on developing innovative cancer therapies. The company specializes in discovering first-in-class small molecule therapeutics that address unmet needs in oncology. ChromaCure's primary goal is to identify potential new drug candidates that selectively and potently inhibit cancer targets, offering novel treatment options for various forms of cancer. These therapies are designed to be used either as monotherapy or in combination with existing treatments such as immunotherapy or chemotherapy, aiming to provide more effective solutions for cancer patients.

Escalier Biosciences B.V. is a biopharmaceutical company based in Nijmegen, the Netherlands, specializing in the development of small molecule therapeutics aimed at treating autoimmune disorders, particularly psoriasis. Founded in 2016, the company is engaged in creating innovative drug candidates that effectively target ROR?t, a critical regulator in the inflammatory process. Escalier's lead products, which are designed for both topical and oral administration, are currently in late-stage preclinical studies. These therapeutics are formulated to enhance penetration in dermal tissues, thereby maximizing target engagement at sites of inflammation while minimizing systemic drug activity and associated side effects. In addition to its operations in the Netherlands, Escalier has an office in Encinitas, California.

NorthSea Therapeutics B.V. is a biotechnology company based in Naarden, the Netherlands, focused on developing and manufacturing innovative therapeutics for metabolic, inflammatory, and fibrotic diseases. Founded in 2017, the company utilizes its proprietary Structurally Engineered Fatty Acid (SEFA) technology to create unique oral therapeutics, including icosabutate, which targets inflammatory and liver diseases. NorthSea Therapeutics aims to address various health conditions, such as dyslipidemia, insulin resistance, hepatic inflammation, and fibrosis, by delivering therapies that offer diverse biological effects. The company's pipeline reflects its commitment to advancing treatment options that enhance patient care and outcomes.

Zeotap GmbH is a customer intelligence platform founded in 2014 and headquartered in Berlin, Germany, with additional offices in New York, Bengaluru, Madrid, and Milan. The company helps brands understand their customers and predict behaviors through its suite of data solutions, which includes the Zeotap Customer Data Platform (CDP), Zeotap Data, and Zeotap ID+. The Zeotap CDP allows brands to integrate, unify, segment, and orchestrate customer data securely and effectively. Zeotap Data enables targeted marketing at scale with access to a wide range of Champion Segments across various platforms. The Zeotap ID+ initiative provides a universal marketing ID to facilitate addressability in a future without cookies. Committed to privacy, Zeotap's platform adheres to stringent data security and privacy standards, empowering brands to leverage first-party data for enhanced customer engagement and loyalty.

Caringo, Inc. is a software company specializing in object storage solutions designed for managing unstructured data. Founded in 2005 and based in Austin, Texas, the company offers a range of products including its flagship CAStor, which facilitates private cloud storage and enables customers to build storage clusters without reliance on proprietary hardware. Other notable offerings include the Content Router for automated data distribution, the FileFly platform for managing infrequently accessed data on Microsoft Windows servers, and the Elastic Content Protection solution for adaptable data protection based on varying storage requirements. Additionally, Caringo provides tools such as CloudScaler for cloud storage as a service, Indexer for data insights, and Swarm, which addresses challenges in big data storage and content delivery. Its clientele ranges from small to medium-sized businesses to Fortune 500 companies, reflecting its broad applicability in the data management landscape.

BrightVolt, Inc. is a company focused on the design, development, and large-scale manufacturing of ultra-thin film batteries tailored to power a range of Internet-connected devices, including medical patches, sensor labels, and power cards. It specializes in creating custom solid-state thin film batteries and power solutions for clients' Internet of Things (IoT) devices, along with its proprietary Flexion solid-state thin film lithium polymer batteries and microelectronic components. BrightVolt's innovative technologies enhance battery chemistry, offering increased stability and safety in lithium-polymer batteries. The company's products are distributed both in the United States and internationally. Founded in 1998 and headquartered in Redmond, Washington, BrightVolt was previously known as Solicore, Inc.

VUV Analytics, Inc. is a manufacturer and marketer of vacuum ultraviolet (VUV) detectors, specializing in advanced chemical analysis technologies. Founded in 2009 and based in Cedar Park, Texas, the company emerged as a spin-off from a semiconductor equipment firm, leveraging the expertise of its founders in hardware, software, and intellectual property related to VUV technologies. VUV Analytics produces instruments such as the VGA-100, a VUV absorption spectroscopy device, and gas chromatography detectors that facilitate the identification and quantification of various compounds. The company serves a diverse range of industries, including petroleum and natural gas, environmental science, specialty gases, petrochemicals, agrochemicals, forensics, and food and beverage safety. By harnessing light to create spectral signatures in the gas phase, VUV Analytics enhances the accuracy of chemical analysis, enabling customers to achieve unambiguous compound identification and quantitative results across complex applications.

Kateeva, formerly known as TJet Technologies, specializes in developing inkjet printing equipment for the production of organic light-emitting diode (OLED) displays. The company's innovative manufacturing solutions enable the mass production of flexible and large-size OLEDs, offering significant advantages in terms of longer lifespans, higher yields, and reduced production costs. This technology represents a breakthrough in the display industry, making it economically viable to produce OLEDs at scale. Kateeva's equipment can print billions of pixels rapidly, paving the way for advanced flat panel displays, including flexible and foldable products. This advancement not only enhances consumer electronics, making high-quality displays more accessible, but also fosters a new wave of innovation in the technology sector.

Cambridge Epigenetix Limited is a bioscience company based in Babraham, United Kingdom, specializing in epigenetic tools that aim to transform medical diagnostics. Founded in 2012 as a spin-out from the University of Cambridge, the company is pioneering the clinical applications of epigenetics, particularly through its innovative TrueMethyl technology. This includes oxidative bisulfite sequencing, which allows for the precise sequencing of hydroxymethyl cytosine and methylcytosine at single-base resolution. Cambridge Epigenetix offers a range of products, such as TrueMethyl 6 and TrueMethyl 24 kits, designed for the quantitative measurement and analysis of these critical epigenetic markers. The company’s research highlights the significance of 5-hydroxymethylcytosine as a biomarker for various diseases, including colorectal cancer, and aims to simplify diagnostic processes to a simple blood draw. The firm collaborates with third-party vendors and sells its products directly to business customers both in the UK and internationally.

Svelte Medical Systems, founded in 2007 by Robert Fischell, David Fischell, and Tim Fischell, specializes in the design, development, and commercialization of balloon-expandable stents for treating atherosclerosis via percutaneous coronary intervention (PCI). The company offers two primary products: SLENDER Integrated Delivery System (IDS), a drug-eluting stent-on-a-wire system that facilitates transradial interventions by downsizing catheters; and DIRECT Rapid Exchange System (RX), a drug-eluting stent designed to enhance direct stenting and high-pressure post-dilatations. Svelte aims to improve stent deliverability, reduce costs, and enhance safety compared to existing market products in the $5 billion coronary stent market.

Akarna Therapeutics Ltd. is a biopharmaceutical company focused on developing small molecule therapeutics for inflammatory and fibrotic diseases. Established in 2014, the company operates out of offices in Cambridge, United Kingdom, and San Diego, California. Akarna's lead program centers on a non-bile acid FXR agonist, which aims to provide a best-in-class therapeutic option for treating nonalcoholic steatohepatitis (NASH), a severe form of fatty liver disease with no currently approved treatments. At present, the lead candidate is undergoing preclinical studies, including IND-enabling toxicology and safety pharmacology assessments, with plans to initiate first-in-human trials.

Ovizio is a company that specializes in digital holographic interferometric microscopy products, particularly focusing on the development of automated systems for cell culture monitoring and analysis. Its innovative technology enables the creation of four-dimensional microscopic imaging devices and accompanying software, specifically designed to assist scientists and biomanufacturers in optimizing and scaling their cell culture processes. By targeting the life sciences bio-processing segment and the research and development market, Ovizio aims to enhance the efficiency and effectiveness of scientific endeavors in these fields.

Fuzzy Logix, LLC is an analytics software and professional services company based in Charlotte, North Carolina, founded in 1995. The company specializes in in-database analytics solutions, which allow organizations to perform complex analytical computations directly within their databases, eliminating the need for data extraction and intermediate processing. Its primary product, DB Lytix, serves quantitative analysts and application developers by accelerating model development and enabling in-database scoring. Fuzzy Logix also offers a range of financial analytics solutions, a graphics processing unit analytic appliance loaded with a comprehensive library of algorithms, and text and name matching capabilities. In addition to its software offerings, Fuzzy Logix provides various advisory services, including analytics and technology consulting, cloud analytics, managed services, and custom model development. The company caters to diverse sectors, including finance, insurance, marketing, retail, and healthcare, and distributes its products both directly and through resellers, serving clients in the United States and internationally.

EXTEN Technologies, Inc. specializes in designing, developing, and manufacturing high-performance non-volatile memory flash storage solutions tailored for web-scale, enterprise, and cloud data centers. Founded in 2011 and based in Austin, Texas, the company focuses on accelerating application workloads while minimizing system power consumption. EXTEN Technologies provides a range of products, including flash storage arrays and solid-state drives, alongside support and service planning, training, and professional design services. Its storage solutions are engineered to meet the demands of high-performance, low-latency workloads prevalent in sectors such as e-commerce, real-time analytics, video processing, and financial trading. Serving a global clientele through an extensive network of resellers and partners, EXTEN Technologies is recognized as a pioneer in ultra-high-performance storage software applications. As of August 2020, it operates as a subsidiary of OVH SAS.

VORAGO Technologies Inc. is a fabless semiconductor company that specializes in designing, manufacturing, and testing radiation-hardened and extreme temperature-hardened integrated circuit components for the high-reliability market. Founded in 2004 and headquartered in Austin, Texas, the company offers a range of products including high-density SRAMs, microcontrollers, and application-specific integrated circuits (ASICs) tailored for applications in automotive, industrial, military, aerospace, and networking sectors. VORAGO utilizes its patented HARDSIL technology, which enhances the reliability and performance of integrated circuits by allowing them to withstand extreme environmental conditions, such as high radiation and temperature levels. This innovative approach provides a robust alternative to traditional methods used in the hi-rel industry, enabling the production of durable and reliable semiconductor components without the need for redesign.

Ralexar Therapeutics, Inc. is a biopharmaceutical company focused on developing and manufacturing topical and systemic therapies that utilize Liver X Receptor (LXR) modulators for treating cutaneous inflammatory disorders, particularly atopic dermatitis. Founded in 2013 and based in Wayne, Pennsylvania, the company was previously known as Alexar Therapeutics before its name change in March 2016. Ralexar's lead product is ALX-101, a topical therapy aimed at improving treatment outcomes for patients suffering from various dermatological conditions. The company's innovative approach aims to facilitate quick initiation of treatment, enhancing the likelihood of successful patient outcomes. Ralexar operates as a subsidiary of NeXeption, LLC.

PerceptiMed, Inc. is a technology company based in Mountain View, California, specializing in medication verification systems designed to minimize human errors in medication dispensing across pharmacies, long-term care facilities, and hospitals. Founded in 2011, the company offers a range of products, including the IdentRx automated medication-verification device, which ensures accurate prescription pill verification and administration. Complementing this device is IdentRx Remote, software that facilitates remote verification of dispensed pills, and MedPass, a system aimed at preventing errors in pill administration. Additionally, PerceptiMed provides ScripClip, an electronic tagging system to enhance medication management. The company's innovative VeriFill technology ensures 100% verification of drug, dosage, and manufacturer for each pill dispensed, positioning PerceptiMed as a leader in the healthcare technology sector.

Vaultive is a provider of cloud data encryption services that addresses critical concerns surrounding cloud data security. The company offers a unique encryption in use technology that allows organizations to retain control and ownership of their data, even when it resides in the cloud. By enabling customers to hold the encryption keys, Vaultive empowers businesses to utilize cloud applications effectively while ensuring compliance, governance, and security. Its services facilitate the processing of encrypted data within cloud applications, allowing for tasks such as searching, indexing, and sorting without the need for decryption. This approach enables organizations to benefit from the efficiency and cost-effectiveness of cloud computing while maintaining the data security and control typically associated with on-premise solutions.

Cambridge Epigenetix Limited is a bioscience company based in Babraham, United Kingdom, specializing in epigenetic tools that aim to transform medical diagnostics. Founded in 2012 as a spin-out from the University of Cambridge, the company is pioneering the clinical applications of epigenetics, particularly through its innovative TrueMethyl technology. This includes oxidative bisulfite sequencing, which allows for the precise sequencing of hydroxymethyl cytosine and methylcytosine at single-base resolution. Cambridge Epigenetix offers a range of products, such as TrueMethyl 6 and TrueMethyl 24 kits, designed for the quantitative measurement and analysis of these critical epigenetic markers. The company’s research highlights the significance of 5-hydroxymethylcytosine as a biomarker for various diseases, including colorectal cancer, and aims to simplify diagnostic processes to a simple blood draw. The firm collaborates with third-party vendors and sells its products directly to business customers both in the UK and internationally.

Kateeva, formerly known as TJet Technologies, specializes in developing inkjet printing equipment for the production of organic light-emitting diode (OLED) displays. The company's innovative manufacturing solutions enable the mass production of flexible and large-size OLEDs, offering significant advantages in terms of longer lifespans, higher yields, and reduced production costs. This technology represents a breakthrough in the display industry, making it economically viable to produce OLEDs at scale. Kateeva's equipment can print billions of pixels rapidly, paving the way for advanced flat panel displays, including flexible and foldable products. This advancement not only enhances consumer electronics, making high-quality displays more accessible, but also fosters a new wave of innovation in the technology sector.

Svelte Medical Systems, founded in 2007 by Robert Fischell, David Fischell, and Tim Fischell, specializes in the design, development, and commercialization of balloon-expandable stents for treating atherosclerosis via percutaneous coronary intervention (PCI). The company offers two primary products: SLENDER Integrated Delivery System (IDS), a drug-eluting stent-on-a-wire system that facilitates transradial interventions by downsizing catheters; and DIRECT Rapid Exchange System (RX), a drug-eluting stent designed to enhance direct stenting and high-pressure post-dilatations. Svelte aims to improve stent deliverability, reduce costs, and enhance safety compared to existing market products in the $5 billion coronary stent market.

TigerConnect is a provider of clinical communication solutions tailored for the healthcare sector, enabling effective collaboration among doctors, nurses, patients, and care providers. Founded in 2010 and headquartered in Santa Monica, California, the company offers a platform that integrates real-time mobile messaging with a user-friendly interface, while prioritizing security and privacy. Trusted by over 4,000 healthcare organizations, TigerConnect processes more than 10 million messages daily and boasts a 99.99% uptime. Its innovative products and seamless integrations with essential hospital systems enhance workflow efficiency, ultimately accelerating productivity, reducing costs, and improving patient outcomes. The company's commitment to client success is evident through its dedicated support organization, which collaborates with clients to optimize communication workflows and maximize return on investment.

NeXeption, LLC is a biopharmaceutical management company that brings together product opportunities, management expertise and the necessary funding to reach compelling partnership milestones. The NeXeption management team has a proven track record in raising capital, operating development stage companies and forming strategic partnerships to advance products for the benefit of patients.

Ario Pharma Ltd is engaged in the development of therapeutic drugs aimed at treating respiratory conditions. The company is focused on evaluating the anti-tussive properties of XEN-D0501, a potential best-in-class TRPV1 inhibitor, through Phase 2 clinical trials. In addition to its respiratory focus, Ario Pharma is also developing a range of small-molecule TRPV1 antagonists that target neuropathic and inflammatory pain. The company is backed by a highly experienced development team and is supported by leading experts in respiratory disease, ensuring a robust approach to drug development.

BrightVolt, Inc. is a company focused on the design, development, and large-scale manufacturing of ultra-thin film batteries tailored to power a range of Internet-connected devices, including medical patches, sensor labels, and power cards. It specializes in creating custom solid-state thin film batteries and power solutions for clients' Internet of Things (IoT) devices, along with its proprietary Flexion solid-state thin film lithium polymer batteries and microelectronic components. BrightVolt's innovative technologies enhance battery chemistry, offering increased stability and safety in lithium-polymer batteries. The company's products are distributed both in the United States and internationally. Founded in 1998 and headquartered in Redmond, Washington, BrightVolt was previously known as Solicore, Inc.

Dezima Pharma B.V., founded in 2012 and located in Naarden, the Netherlands, specializes in the development of protein-based compounds aimed at treating cardiovascular diseases associated with dyslipidemia. The company focuses on creating innovative drug therapies, particularly a cholesteryl ester transfer protein inhibitor, which is designed to reduce low-density lipoprotein cholesterol levels. This pharmacological approach aims to lower the risk of cardiovascular diseases, thereby providing clinicians with effective treatment options for dyslipidemic patients.

Resolve Therapeutics, LLC is a clinical-stage biopharmaceutical company based in Seattle, Washington, focused on developing innovative biological therapies for autoimmune diseases, particularly systemic lupus erythematosus and Sjögren's syndrome. The company is advancing its lead product candidates, RSLV-132 and RSLV-133, which are designed to target and degrade immune complexes that contribute to disease pathology. RSLV-132 is a mono-specific nuclease Fc-fusion protein aimed at preventing interferon activation and mitigating kidney damage, while RSLV-133 combines two different nuclease activities into a single therapeutic molecule. Founded in 2010, Resolve Therapeutics is rooted in pioneering research from the University of Washington School of Medicine, with a commitment to improving the lives of patients suffering from these chronic conditions.

Achronix Semiconductor Corp. is a privately held fabless semiconductor company based in Santa Clara, California, specializing in the development of high-density and high-performance application-targeted field programmable gate arrays (FPGAs). Its flagship product line, Speedster22i, utilizes Intel's advanced 22nm process technology and integrates hard IP protocol functions tailored for communications applications. Achronix also provides Speedcore eFPGA IP for integration into customers' system-on-chips (SoCs) aimed at compute and network acceleration. The company offers a robust design-tool suite known as the Achronix CAD Environment (ACE), which supports industry-standard synthesis tools. Achronix serves a variety of markets, including networking, optical/telecom, high-performance computing, test and measurement, and military and security. Founded in 2004, Achronix distributes its products through a network that spans North America, Europe, Israel, China, and Russia, with additional research and development facilities located in Bangalore, India.

Juventas Therapeutics, Inc. is a clinical-stage biotechnology company based in Cleveland, Ohio, founded in 2007. The company specializes in developing non-viral gene therapies aimed at activating the body's natural repair processes. Its primary focus is on treating non-healing wounds in patients with advanced peripheral artery disease. The flagship product, JVS-100, is a non-viral gene therapy that expresses stromal cell-derived factor-1 (SDF-1), a signaling protein that helps recruit the body's stem cells and promotes tissue repair across various disease states. Juventas has transitioned its therapeutic platform from concept to the initiation of mid-stage clinical trials, underpinned by exclusive licensing from the Cleveland Clinic and supported by various investors and grants.

Vaultive is a provider of cloud data encryption services that addresses critical concerns surrounding cloud data security. The company offers a unique encryption in use technology that allows organizations to retain control and ownership of their data, even when it resides in the cloud. By enabling customers to hold the encryption keys, Vaultive empowers businesses to utilize cloud applications effectively while ensuring compliance, governance, and security. Its services facilitate the processing of encrypted data within cloud applications, allowing for tasks such as searching, indexing, and sorting without the need for decryption. This approach enables organizations to benefit from the efficiency and cost-effectiveness of cloud computing while maintaining the data security and control typically associated with on-premise solutions.

TigerConnect is a provider of clinical communication solutions tailored for the healthcare sector, enabling effective collaboration among doctors, nurses, patients, and care providers. Founded in 2010 and headquartered in Santa Monica, California, the company offers a platform that integrates real-time mobile messaging with a user-friendly interface, while prioritizing security and privacy. Trusted by over 4,000 healthcare organizations, TigerConnect processes more than 10 million messages daily and boasts a 99.99% uptime. Its innovative products and seamless integrations with essential hospital systems enhance workflow efficiency, ultimately accelerating productivity, reducing costs, and improving patient outcomes. The company's commitment to client success is evident through its dedicated support organization, which collaborates with clients to optimize communication workflows and maximize return on investment.

Oxyrane UK Limited is a biopharmaceutical company focused on developing innovative enzyme replacement therapies for lysosomal storage diseases, a group of over 40 rare inherited disorders. Established in 2006 and headquartered in Manchester, United Kingdom, Oxyrane utilizes a proprietary glycoengineering platform based on the yeast Yarrowia lipolytica to produce human lysosomal enzymes that enhance enzyme uptake and localization in patients. This approach aims to facilitate quicker treatment initiation and improve the likelihood of successful outcomes. The company also has research facilities in Ghent, Belgium, and Burlington, Massachusetts, underscoring its commitment to advancing therapeutic solutions for these complex conditions.

Resolve Therapeutics, LLC is a clinical-stage biopharmaceutical company based in Seattle, Washington, focused on developing innovative biological therapies for autoimmune diseases, particularly systemic lupus erythematosus and Sjögren's syndrome. The company is advancing its lead product candidates, RSLV-132 and RSLV-133, which are designed to target and degrade immune complexes that contribute to disease pathology. RSLV-132 is a mono-specific nuclease Fc-fusion protein aimed at preventing interferon activation and mitigating kidney damage, while RSLV-133 combines two different nuclease activities into a single therapeutic molecule. Founded in 2010, Resolve Therapeutics is rooted in pioneering research from the University of Washington School of Medicine, with a commitment to improving the lives of patients suffering from these chronic conditions.

Lightwire is a telecommunications company focused on developing innovative interconnect solutions that enhance networking, communication, server, and storage systems. The company specializes in the integration of optical and electrical technologies, primarily utilizing CMOS photonics to create high-speed interconnects. Its product offerings include Ethernet optoelectronic interconnects and optical transceiver modules, designed to facilitate seamless, plug-and-play 10Gbps interfaces between computers, servers, and Ethernet-based network equipment. Lightwire's mission is to support the next generation of telecommunications infrastructure through efficient and effective connectivity solutions for businesses.

Celleration Inc. is a privately held medical device company based in Eden Prairie, Minnesota, founded in 1999. The company specializes in developing and commercializing therapeutic ultrasound technologies for wound care. Its flagship product, the MIST Therapy System, utilizes low-frequency ultrasound delivered through a saline mist to promote healing in wounds. This innovative approach allows ultrasound energy to penetrate beyond the surface of the wound, stimulating cellular activity and enhancing the healing process. Since receiving FDA clearance in 2005, Celleration has established a strong presence in the U.S. market, with over 1 million MIST Therapy treatments performed, benefiting more than 65,000 patients across numerous healthcare facilities. Celleration's commitment to advancing wound care technology has resulted in significant clinical and economic benefits, reinforcing its role in the medical community.

ProterixBio, Inc. is a biomedical company based in Billerica, Massachusetts, focused on developing disease management platforms for chronic respiratory diseases. The company specializes in proprietary blood-based biomarker tests aimed at transforming the management of conditions such as chronic obstructive pulmonary disease, cystic fibrosis, and idiopathic pulmonary fibrosis. ProterixBio's ViBE platform, along with its Acoustic Membrane MicroParticle (AMMP) assays, facilitates the precise analysis of proteins in various sample types, delivering real-time biological assessments of a patient's disease state. This technological innovation enhances the sensitivity and specificity of traditional testing methods, allowing healthcare providers to make informed decisions that help reduce hospitalizations and improve patient outcomes, ultimately lowering healthcare costs. Founded in 2002, ProterixBio seeks to address the unmet needs in chronic care management through its advanced diagnostic capabilities.

Seahorse Bioscience specializes in providing analytical instruments, biomanufacturing systems, and consumable labware for biological research and drug discovery. The company is known for its Seahorse extracellular flux (XF) analyzers, which allow for non-invasive profiling of cellular metabolic activity. These instruments enable researchers to assess key metabolic parameters, such as basal oxygen consumption, glycolysis rates, ATP turnover, and respiratory capacity, thereby facilitating the study of mitochondrial dysfunction. Seahorse Bioscience serves a diverse clientele, including scientists at academic institutions, pharmaceutical and biotech companies, and original equipment manufacturers of assay kits and laboratory instruments.

BioVex Group is a biotechnology company specializing in the development and commercialization of biological treatments for cancer and infectious diseases. Its primary focus is OncoVEXGM-CSF, an oncolytic vaccine designed to target and destroy cancer cells while preserving surrounding healthy tissues. This innovative therapy utilizes a virus that replicates within solid tumors, leading to their destruction and stimulating a robust systemic immune response against the cancer. OncoVEXGM-CSF has undergone extensive clinical testing with over 110 patients across various solid tumors, including melanoma, head and neck cancer, breast cancer, and pancreatic cancer. The treatment has demonstrated significant efficacy, routinely eliminating tumors at the injection site and resulting in overall disease responses during Phase II trials. Additionally, BioVex is developing ImmunoVEXHSV2, a vaccine aimed at preventing genital herpes, further expanding its portfolio in biologic therapies.

Seahorse Bioscience specializes in providing analytical instruments, biomanufacturing systems, and consumable labware for biological research and drug discovery. The company is known for its Seahorse extracellular flux (XF) analyzers, which allow for non-invasive profiling of cellular metabolic activity. These instruments enable researchers to assess key metabolic parameters, such as basal oxygen consumption, glycolysis rates, ATP turnover, and respiratory capacity, thereby facilitating the study of mitochondrial dysfunction. Seahorse Bioscience serves a diverse clientele, including scientists at academic institutions, pharmaceutical and biotech companies, and original equipment manufacturers of assay kits and laboratory instruments.

Achronix Semiconductor Corp. is a privately held fabless semiconductor company based in Santa Clara, California, specializing in the development of high-density and high-performance application-targeted field programmable gate arrays (FPGAs). Its flagship product line, Speedster22i, utilizes Intel's advanced 22nm process technology and integrates hard IP protocol functions tailored for communications applications. Achronix also provides Speedcore eFPGA IP for integration into customers' system-on-chips (SoCs) aimed at compute and network acceleration. The company offers a robust design-tool suite known as the Achronix CAD Environment (ACE), which supports industry-standard synthesis tools. Achronix serves a variety of markets, including networking, optical/telecom, high-performance computing, test and measurement, and military and security. Founded in 2004, Achronix distributes its products through a network that spans North America, Europe, Israel, China, and Russia, with additional research and development facilities located in Bangalore, India.

Celleration Inc. is a privately held medical device company based in Eden Prairie, Minnesota, founded in 1999. The company specializes in developing and commercializing therapeutic ultrasound technologies for wound care. Its flagship product, the MIST Therapy System, utilizes low-frequency ultrasound delivered through a saline mist to promote healing in wounds. This innovative approach allows ultrasound energy to penetrate beyond the surface of the wound, stimulating cellular activity and enhancing the healing process. Since receiving FDA clearance in 2005, Celleration has established a strong presence in the U.S. market, with over 1 million MIST Therapy treatments performed, benefiting more than 65,000 patients across numerous healthcare facilities. Celleration's commitment to advancing wound care technology has resulted in significant clinical and economic benefits, reinforcing its role in the medical community.

TherOx, Inc., established in 1994 and headquartered in Irvine, California, is a privately-held medical device company focused on improving heart attack treatment standards. It specializes in developing dissolved oxygen delivery systems, notably its SuperSaturated Oxygen Therapy (SSO2), which involves creating supersaturated oxygenated blood using the TherOx DownStream system for delivery to coronary arteries. This therapy has shown promise beyond initial heart attack treatment, with potential applications in stroke, oncology, and wound care. As of June 18, 2019, TherOx operates as a subsidiary of ZOLL Medical Corporation. The company holds 20 issued patents, with more pending, reflecting its extensive research and development efforts.

BioVex Group is a biotechnology company specializing in the development and commercialization of biological treatments for cancer and infectious diseases. Its primary focus is OncoVEXGM-CSF, an oncolytic vaccine designed to target and destroy cancer cells while preserving surrounding healthy tissues. This innovative therapy utilizes a virus that replicates within solid tumors, leading to their destruction and stimulating a robust systemic immune response against the cancer. OncoVEXGM-CSF has undergone extensive clinical testing with over 110 patients across various solid tumors, including melanoma, head and neck cancer, breast cancer, and pancreatic cancer. The treatment has demonstrated significant efficacy, routinely eliminating tumors at the injection site and resulting in overall disease responses during Phase II trials. Additionally, BioVex is developing ImmunoVEXHSV2, a vaccine aimed at preventing genital herpes, further expanding its portfolio in biologic therapies.

Ikonisys, Inc. is a medical diagnostic company focused on the design, manufacture, and marketing of advanced diagnostic products for cancer detection and genetic disorder screening. Headquartered in New Haven, Connecticut, Ikonisys offers a range of innovative tools, including the Ikoniscope Robotic Microscope, which automates slide handling and image analysis, reducing human error in testing. Their product line features various oncoFISH applications, such as those for bladder cancer and HER2 status in breast tissue, as well as tools for detecting genetic abnormalities in prostate tissue biopsies. The company is committed to transforming diagnostic medicine by enabling early and accurate disease detection through a combination of cutting-edge technology and scientific research, ultimately assisting healthcare professionals in providing optimal patient care. Founded in 1999, Ikonisys continues to advance its capabilities in non-invasive diagnostic solutions.

FlowCardia, Inc. is a medical device company established in 2002 that specializes in developing innovative catheter-based technologies aimed at facilitating guidewire crossing of chronic total occlusions (CTOs) in both coronary and peripheral arteries. CTOs pose significant challenges in interventional therapy, often leading to patients being referred for more invasive procedures such as bypass surgery or limb amputation due to the lack of effective recanalization devices. FlowCardia is dedicated to addressing this critical need within the medical community by providing advanced solutions that enhance the safety and efficacy of CTO recanalization.

BioProcessors is an online platform that assists its clients in the development of drugs. BioProcessors was launched in 2000 and is based in California.

Xoft, Inc. specializes in the development of electronic brachytherapy (eBx) systems designed for radiation oncology applications. The company’s flagship product, the Axxent Controller, employs a miniaturized high dose rate X-ray source to deliver targeted radiation directly to cancerous tumor beds. Xoft also provides a range of applicators, including the Axxent balloon applicator for accelerated partial breast irradiation, the Axxent vaginal applicator for vaginal brachytherapy, and the Axxent surface applicator for treating surface lesions. Additionally, the company offers a variety of accessories to support its products, such as physics accessory kits and protective shields to minimize radiation exposure to healthy tissues. Xoft’s innovative solutions are primarily utilized in the treatment of early-stage breast cancer, skin cancer, and endometrial cancer, and the products are distributed through physicians and distributors across Europe. Founded in 1998 and based in Sunnyvale, California, Xoft was previously known as Xoft microTube, Inc. before rebranding in 2004.

Ception Therapeutics is a biopharmaceutical company dedicated to the discovery and development of innovative therapeutics aimed at addressing significant unmet medical needs. Founded by seasoned pharmaceutical executives, the company is engaged in the commercialization of novel drugs and therapies for challenging illnesses. Ception's portfolio includes Reslizumab, which targets eosinophilic inflammatory conditions, and a class of small molecule anti-TNF receptor agents designed for potential oral administration. In addition, the company is actively developing treatments for central nervous system disorders, pain, and cancer, featuring eight proprietary products in the United States and over 100 products available internationally. Ception's research efforts are focused on creating new compounds and exploring new indications for existing therapies, underscoring its commitment to advancing healthcare solutions.

Achronix Semiconductor Corp. is a privately held fabless semiconductor company based in Santa Clara, California, specializing in the development of high-density and high-performance application-targeted field programmable gate arrays (FPGAs). Its flagship product line, Speedster22i, utilizes Intel's advanced 22nm process technology and integrates hard IP protocol functions tailored for communications applications. Achronix also provides Speedcore eFPGA IP for integration into customers' system-on-chips (SoCs) aimed at compute and network acceleration. The company offers a robust design-tool suite known as the Achronix CAD Environment (ACE), which supports industry-standard synthesis tools. Achronix serves a variety of markets, including networking, optical/telecom, high-performance computing, test and measurement, and military and security. Founded in 2004, Achronix distributes its products through a network that spans North America, Europe, Israel, China, and Russia, with additional research and development facilities located in Bangalore, India.

BioProcessors is an online platform that assists its clients in the development of drugs. BioProcessors was launched in 2000 and is based in California.

Ikonisys, Inc. is a medical diagnostic company focused on the design, manufacture, and marketing of advanced diagnostic products for cancer detection and genetic disorder screening. Headquartered in New Haven, Connecticut, Ikonisys offers a range of innovative tools, including the Ikoniscope Robotic Microscope, which automates slide handling and image analysis, reducing human error in testing. Their product line features various oncoFISH applications, such as those for bladder cancer and HER2 status in breast tissue, as well as tools for detecting genetic abnormalities in prostate tissue biopsies. The company is committed to transforming diagnostic medicine by enabling early and accurate disease detection through a combination of cutting-edge technology and scientific research, ultimately assisting healthcare professionals in providing optimal patient care. Founded in 1999, Ikonisys continues to advance its capabilities in non-invasive diagnostic solutions.

Light Sciences Oncology, Inc. is a biotechnology company focused on developing and manufacturing talaporfin sodium, a water-soluble drug for the treatment of solid tumors and other medical indications. The company specializes in providing innovative oncology solutions, including a single-use, LED-based drug activator that delivers a precise light dose to enhance treatment efficacy. Its primary applications include the treatment of hepatocellular carcinoma, metastatic colorectal cancer, and benign prostatic hyperplasia. Founded in 1994 and headquartered in Bellevue, Washington, Light Sciences Oncology combines advanced drug development with a commitment to improving patient care through non-invasive treatment options.

TherOx, Inc., established in 1994 and headquartered in Irvine, California, is a privately-held medical device company focused on improving heart attack treatment standards. It specializes in developing dissolved oxygen delivery systems, notably its SuperSaturated Oxygen Therapy (SSO2), which involves creating supersaturated oxygenated blood using the TherOx DownStream system for delivery to coronary arteries. This therapy has shown promise beyond initial heart attack treatment, with potential applications in stroke, oncology, and wound care. As of June 18, 2019, TherOx operates as a subsidiary of ZOLL Medical Corporation. The company holds 20 issued patents, with more pending, reflecting its extensive research and development efforts.

BioProcessors is an online platform that assists its clients in the development of drugs. BioProcessors was launched in 2000 and is based in California.